本季度信息
加科思-B公布2026年中期业绩，截至2026年6月30日止六个月内，实现营收7.31亿元，同比上年同期的0.46亿元增长约1499.3%。期内经调整净利润6.03亿元，而上年同期为亏损0.56亿元。公司表示，收入大幅增长主要来自与AstraZeneca就JAB-23E-73开展在研发、生产及商业化方面的战略合作，以及与艾力斯就艾瑞凯和sitneprotafib开展的外部授权及服务协议。
报告期内研发投入约为0.92亿元，较上年同期的0.93亿元略微下降。公司称，这主要受到员工成本优化所驱动，但研发管线相关临床项目仍按计划推进。行政开支维持在约0.19亿元，反映持续优化和运营效率提升的成果。期内经营活动产生的现金流量净额约5.93亿元，上年同期则为净流出1.43亿元。
业务分项
公司业务板块主要聚焦创新药物研发与商业化。报告显示，JAB-23E-73在内的研发与许可为收入增长的关键因素；同时，艾瑞凯与sitneprotafib在大中华区的商业化与外部许可也带来了较大贡献。
高管解读 （无直接引文，故此部分暂无内容）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.